Toxoplasmic encephalitis in an AIDS cohort at Puerto Rico before and after Highly Active Antiretroviral Therapy (HAART)

American Journal of Tropical Medicine and Hygiene

Volumn 84, Issue 5, 2011, Pages 838-841

  Mayor, Angel M ^a   Fernández Santos, Diana M ^a   Dworkin, Mark S ^b   Ríos Olivares, Eddy ^a   Hunter Mellado, Robert F ^a  

^a Universidad Central del Caribe School of Medicine   (Puerto Rico)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPPORTUNISTIC INFECTION; PROPORTIONAL HAZARDS MODEL; PUERTO RICO; TOXOPLASMOSIS; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; PUERTO RICO; TOXOPLASMOSIS, CEREBRAL;

EID: 79958722396     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2011.10-0718     Document Type: Article

References (13)

1. Abgrall S, Rabaud C, Costagliola D, 2001. Incidence and risk factors for toxoplasmic encephalitis in HIV-infected patients before and during the HAART era. Clin Infect Dis 33: 1747-1755. (Pubitemid 33044543)
2. Montoya JG, Remington JS, 2000. Toxoplasma gondii. Mandell GL, Bennett JE, Odolin R, eds. Principles and Practice of Infectious Diseases. Philadelphia, PA: Churchill Livingstone, 2858-2888.
3. Luft BJ, Rennington JS, 1992. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 15: 211-222.
4. Pozio E, 2004. Highly Active Antiretroviral Therapy and opportunistic protozoan infections. Parassitolog 46: 89-93. (Pubitemid 40063855)
5. Antinorio A, Larussa D, Cingolani A, Lorenzini P, Bossolasco S, Finazzi MG, Bongiovanni M, Guaraldi G, Grisetti S, Vigo B, Gigli B, Mariano A, Dalle Nogare E, De Marco M, Moretti F, Corsi P, Abrescia N, Rellecati P, Castagna A, Mussini C, Ammassari A, Cinque P, d'Arminio Monfort A, 2004. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis 39: 1681-1691.
6. Jones JL, Hanson DL, Dworkin MS, Alderton DL, Fleming PL, Kaplan JE, Ward J, 1999. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ 48: 1-22.
7. CDC, 2006. HIV/AIDS Surveillance Report. Cases of HIV Infection and AIDS in the United States and Dependent Areas.
8. Báez-Feliciano DV, Thomas JC, Gómez MA, Miranda S, Fernández DM, Velázquez M, Ríos-Olivares E, Hunter-Mellado RF, 2005. Changes in the AIDS epidemiologic situation in Puerto Rico following health care reform and the introduction of HAART. Rev Panam Salud Publica 17: 92-101. (Pubitemid 40344335)
9. Hoffmann C, Ernst M, Meyer P, Wolf E, Rosenkranz T, Plettenberg A, Stoehr A, Horst HA, Marienfeld K, Lange C, 2007. Evolving characteristics of toxoplamosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specifi immune response. Clin Microbiol Infect 13: 510-515. (Pubitemid 46563501)
10. Cohen O, Weissman D, Fauci AS, 1999. The immunopathogenesis of HIV infection. Paul WE, ed. Fundamental Immunology. Philadelphia, PA: Lippincott-Raven, 1455-1509.
11. Contini C, 2008. Clinical and diagnostic management of toxoplasmosis in the immunocompromised patients. Parassitol 50: 45-50.
12. Subauste CS, Remington JS, 1999. Immunity to Toxoplasma gondii . Curr Opin Immunol 4: 532-537.
13. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H, 2009. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 58: 13-18.